Phase I Study of gemtuzumab ozogamicin in combination with cytarabinne [cytarabine] and daunorubicin as induction therapy for relapsed or refractory patients with acute myeloid leukemia.

Trial Profile

Phase I Study of gemtuzumab ozogamicin in combination with cytarabinne [cytarabine] and daunorubicin as induction therapy for relapsed or refractory patients with acute myeloid leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Daunorubicin (Primary) ; Gemtuzumab ozogamicin (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 31 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 29 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top